Sixteen patients (5 female and 11 male, mean age 59.1 years) who had had an acute myocardial infarction within the previous 7 days, were enrolled in an open pharmacodynamic study. Patients were randomly allocated to two treatment groups and given a single subcutaneous dose of 100 or 200 mg of a new low-molecular-weight dermatan sulphate. The drug pharmacodynamic profile was determined 1, 2, 4, 6, 8, 12 and 24 h after administration. The following coagulation and fibrinolysis tests were performed: activated partial thromboplastin time, thrombin time, activated factor X inhibition, Heptest (global clotting time), heparin cofactor II affinity, functional and antigenic plasminogen activator inhibitor and fibrin plate assay. Both Heptest and heparin cofactor II affinity were significantly increased (P < 0.001) in a dose-dependent manner. The Xal was enhanced, though to a lesser extent. None of the other coagulation or fibrinolysis tests showed significant changes at either dose. Systemic and local tolerance were always very good.
ACC/AHA Task Force Report: Guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol1990; 16: 249–292.
2.
SteinB, FusterV: Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thromboembolism. Am J Cardiol1989; 64: 33B–40B.
3.
TurpieAG, RobinsonJC, DoyleDJ: Prevention of left ventricular mural thrombosis in acute transmural anterior myocardial infarction: a double blind trial comparing high dose with low dose subcutaneous calcium heparin. N Engl J Med1989; 320: 352–357.
4.
HullRD, PineoGF: Therapeutic use of low-molecular-weight heparins. Haemostasis1993; 23 (suppl 1): 2–9.
5.
TollfsenDM, PestkaCA, MonafoWJ: Activation of heparin cofactor II by dermatan sulphate. J Biol Chem1983; 258: 6713–6716.
6.
DesnoyersP, BaraL, SamamaM: Dermatan-sulfate et prevention des thromboses veineuses experimentales. Pathol Biol (Paris)1989; 37: 759–767.
7.
BergonziniG, BianchiniP, HoppensteadtD: Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates. Sem Thromb Hemost1991, 17 (suppl 2): 235–239.
8.
MascellaniG, BianchiniP: European Patent 1990, No 0221977. USA Patent 1990, No 4973580.
9.
BarbantiM, Calanni RindinaF, ColucciM: Thrombolytic activity of Desmin 370 in a venous thrombosis model in the rat: comparison with Urokinase, (abstract)Thromb Haemost1991; 65: 1086.
10.
BarbantiM, CalanniF, MarchiE: Therapeutic efficacy of a low molecular weight dermatan sulphate (Desmin 370) in experimental venous thrombosis in rats: comparison with t-PA and u-PA (abstract). Thromb Haemost1993; 69: 860.
11.
BarbantiM, CalanniF, MilaniMR: Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant-independent mechanism. Thromb Haemost1993; 69: 147–151.
12.
DettoriAG, GalliG, ManottiC: Pharmacological activity of a low molecular weight dermatan sulphate (DESMIN) in healthy volunteers. Semin Thromb Hemost1994; 20: 259–265.
13.
Van Ryn-McKennaJ, OfosuF, GrayE: Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci1989; 556: 304–312.
14.
BarbantiM, Calanni RindinaF, MarchiE: Desmin 370: a low molecular weight dermatan with a potent antithrombotic activity and apparent thrombolytic properties (abstract). Fibrinolysis1990, 4 (suppl 3): 113.
15.
BarbantiM, MarchiE, SemeraroN: Involvement of the fibrinolytic system in the antithrombotic activity of low molecular weight dermatan sulfate (Desmin 370). Semin Thromb Hemost1991; 17 (suppl 1–2): 243.
16.
VenturiniAP, BarbantiM, BertoliD: Toxicological profile of Desmin 370. (abstract)Proceedings of the VIth International Congress of Toxicology, Rome, Italy, June 28 – July 3, 1992; p. 245.
17.
ColucciM, BarbantiM, CalanniF: Desmin 370 (D370), a low molecular weight dermatan sulphate, reduces the size of preformed thrombi in rats made a fibrinogenemic by Ancrod (abstract). Thromb Haemost1993; 69: 860.
DawesJ, LumbersER: Low molecular weight dermatan sulphate (Desmin 370) does not cross the ovine placenta. Br J Haematol1993; 84: 90–94.
20.
DawesJ: The pharmacokinetics of LMW dermatan sulphate: long term persistence of intact material. Thromb Haemost1993; 69: 339–343.
21.
BarbantiM, CalanniF, BabbiniM: Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulphate. Thromb Res1993; 71: 417–422.
22.
LegnaniC, PalaretiG, BiagiR: Acute and chronic clotting and fibrinolytic effects of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Europ J Clin Pharmacol1994; in press.
23.
CucinottaD, ManopuloR, GalatiM: Pharmacodynamics of a new low-mol-ecular-weight-dermatan sulphate after a single s.c. administration in aged patients suffering from chronic phlebopathies. An open, preliminary clinical trial. Curr Ther Res1994; 55: 1–9.
24.
HaverkateF, BrakmanP: Fibrin plate assay. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol. 1 (DavidsonJF, eds). New York: Raven Press, 1975; pp. 151–159.
25.
MelandriG, BranziA, SempriniF: Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction. Thromb Res1992; 66 (2 – 3): 141–150.
26.
LegnaniC, BiagiR, PalaretiG: Anti-Xa activity of a new low molecular weight dermatan sulphate. Thromb Res1993; 70 (suppl 1): 573.
